Regulus aims to develop novel oligonucleotide therapeutics that are designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases.

Home Page Ticker
Press Releases.
March 21, 2024

Positive topline data from the second cohort of patients in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

March 12, 2024

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today...

March 12, 2024

Mechanistic dose response observed at a 2mg/kg dose level based on urinary biomarker analyses Encouraging exploratory results of imaging-based biomarkers with greatest reductions in total kidney...

More press releases

Tuesday, March 12, 2024
8:30am - 9:30am EDT
Wednesday, November 29, 2023
10:25am EST
Wednesday, September 20, 2023
8:30am - 9:30am EDT

More events

upcoming event.
No events to display

more events

corporate presentation.
email alerts.

Sign up for email alerts to receive the latest financial information from Regulus Therapeutics Inc.

Sign Up

IR contact.

Phone: 858-202-6300

Contact Us